drugset / Trial / NCT00692094
Blind Elderly Melatonin Treatment Study
Terminated
12 enrolled
Oregon Health and Science University
National Institute on Aging (NIA) · collab
Non-randomizedParallel-groupSingle-blindTreatment
Summary
The primary focus of this five-year study will be to optimize the melatonin dosing regimen for synchronizing the body clocks of elderly blind individuals to the 24-hour day.
Timeline
- Start
- 2004-08
- Primary completion
- 2008-05
- Completion
- 2008-12
Publications
- Background Lewy AJ. Melatonin as a marker and phase-resetter of circadian rhythms in humans. Adv Exp Med Biol. 1999;460:425-34. doi: 10.1007/0-306-46814-x_51. No abstract available.
- Background Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. 2000 Oct 12;343(15):1070-7. doi: 10.1056/NEJM200010123431503.
- Background Lewy AJ, Bauer VK, Hasler BP, Kendall AR, Pires ML, Sack RL. Capturing the circadian rhythms of free-running blind people with 0.5 mg melatonin. Brain Res. 2001 Nov 9;918(1-2):96-100. doi: 10.1016/s0006-8993(01)02964-x.
- Results Lewy AJ, Emens JS, Lefler BJ, Yuhas K, Jackman AR. Melatonin entrains free-running blind people according to a physiological dose-response curve. Chronobiol Int. 2005;22(6):1093-106. doi: 10.1080/07420520500398064.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melatonin | Small molecule | 0.025 mg | — |
| Subject | Melatonin | Small molecule | 0.5 mg | — |
| Subject | Melatonin | Small molecule | 10 mg | — |
| Subject | Melatonin | Small molecule | 20 mg | — |